Stage of differentiation, proliferative index of tumor cells and cytotoxic activity of peripheral blood lymphocytes in colorectal cancer patients

Experimental Oncology

Volumn 26, Issue 2, 2004, Pages 161-163

  Paholyuk, Tatyana D ^a   Zacharzeva, Lubov M ^b   Koshel, Konstantin V ^b   Oliynichenko, Gennadiy P ^b   Berezhnaya, Ninel M ^a  

^a R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

^b Kyiv Municipal Oncological Hospital   (Ukraine)

Author keywords

Colorectal cancer; Cytotoxic activity; Ki 67; Survival

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; FLUOROURACIL; FOLINIC ACID; MONOCLONAL ANTIBODY KI 67; KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INHIBITION; CANCER STAGING; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL FEATURE; COLORECTAL CANCER; CORRELATION COEFFICIENT; CYTOTOXIC LYMPHOCYTE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MALE; NATURAL KILLER CELL; PERIPHERAL LYMPHOCYTE; POSTOPERATIVE PERIOD; PROGNOSIS; SURVIVAL RATE; TUMOR CELL; TUMOR DIFFERENTIATION; ADJUVANT CHEMOTHERAPY; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOTOXICITY; LYMPH NODE METASTASIS;

ADENOCARCINOMA; CELL DIFFERENTIATION; CELL DIVISION; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; FEMALE; HUMANS; KI-67 ANTIGEN; KILLER CELLS, NATURAL; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 3242793529     PISSN: 02043564     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Berezhnaya NM, Chekhun VF. Immunity system and cancer: achievements and misfortune. Oncologiya 2003; 5: 84-8 (In Russian).
2. Herberman RB. Cancer immunotherapy with natural killer cells. Semin Oncol 2002; 29: 27-30.
3. Diederichsen AC, Stenholm AC, Kronborg O, Fenger C, Jensenius JC, Zeuthen J, Christensen PB, Kristensen T, Ostenhom AC. Flow cytometric investigation of immune-response-related surface molecules on human colorectal cancers. Int J Cancer 1998; 79: 283-7.
4. Maeda Y, Ito M, Harashima N, Nakatsura T, Hida N, Imai N, Sato Y, Shichijo S, Todo S, Itoh K. Cleavage and polyadenylation specificity factor (CPSF)-derived peptides can induce HLA-A2-restricted and tumor-specific CTLs in the majority of gastrointestinal cancer patients. Int J Cancer 2002; 99: 409-17.
5. Tanaka H, Tsunoda T, Nukaya I, Yamana H, Shichijo S. Mapping the HLA-A24-restricted T-cell epitope peptide from a tumour-associated antigen HER2/neu: possible immunotherapy for colorectal carcinomas. Br J Cancer 2001; 84: 94-9.
6. Gri G, Chiodoni C, Gallo E, Stoppacciaro A, Liew FY, Colombo MP. Antitumor effect of interleukin (IL)-12 in the absence of endogenous IFN-gamma: a role for intrinsic tumor immunogenicity and IL-15. Cancer Res 2002; 62: 4390-7.
7. Liljefors M, Nilsson B, Hjelm Skog AL, Iigo M, Itoh T. Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A. Int J Cancer 2003; 105: 717-23.
8. Shpak AR, Pavlova KS, Bulyicheva TI. MTT-colorimetric method for determination of cytotoxic activity of natural killer cells. Immunologiya 2000; 2: 20-3 (In Russian).
9. Bleiberg H, Rougier P, Wilke HJ. Management of colorectal cancer. London: Martin Dunitz Ltd, 1998; 397 p.
10. Paholyuk TD, Koshel KV, Olyinichenko GP, Berezhnaya NM. Cytotoxic activity of lymphocytes from peripheral blood of patients with colorectal cancer. Oncologiya 2004; 6: 46-9 (In Russian).
11. Indar AA, Maxwell-Armstrong CA. Active specific immunotherapy for colorectal cancer. Expert Rev Anticancer Ther 2003; 3: 685-94.
12. Yamaguchi Y, Miyahara E, Ohshita A, Shenton BK, Brotherick I. Locoregional immunotherapy of malignant effusion from colorectal cancer using the streptococcal preparation OK-432 plus interleukin-2: induction of autologous tumor-reactive CD4+ Th1 killer lymphocytes. Br J Cancer 2003; 89: 1876-84.
13. Koesters R, Linnebacher M, Coy JF. WT1 is a tumor-associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T cells. Int J Cancer 2004; 109: 385-92.
14. Kolesnik EA, Potebnya GP, Kikot VA. Antitumor autovaccine for therapy of patients with advanced colorectal cancer. Oncologiya 1999; 2: 104-8 (In Russian).
15. Baars A, Claessen AM, Wagstaff J, Giaccone G, Scheper RJ, Meijer S, Schakel MJ, Gall HE, Meijer CJ, Vermorken JB, Pinedo HM, van den Eertwegh AJ. A phase II study of active specific immunotherapy and 5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma. Br J Cancer 2002; 86: 1230-4.
16. Habal N, Gupta RK, Bilchik AJ, Yee R, Leopoldo Z, Ye W, Elashoff RM, Morton DL. CancerVax, an allogeneic tumor cell vaccine, induces specific humoral and cellular immune responses in advanced colon cancer. Ann Surg Oncol 2001; 8: 389-401.